

Patent Claims

1. An agent for inducing or inhibiting angiogenesis, which comprises isogenic or autologous body cells that express at least one angiogenetic or anti-angiogenetic protein.
2. An agent according to claim 1, wherein the at least one angiogenetic protein is selected from PDGF-A (platelet derived growth factor A), PDGF-B (platelet derived growth factor B), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), TGFbeta (tumour growth factor beta), angiopoetin 1 and angiopoetin.
3. An agent according to claim 1, wherein the at least one anti-angiogenetic protein is selected from VEGFR-1 (vascular endothelial growth factor receptor 1), angiostatin, endostatin and receptor blockers for VEGFR1 and VEGFR2.
4. A method for the production of an agent according to any one of claims 1 to 3, in which
 - a) the formation of isogenic or autologous cells is induced in a body by implantation of biologically inert material,
 - b) the cells formed in step a) are extracted from the body,
 - c) the cells obtained in step b) are genetically modified in such a manner that in the case of a desired induction of angiogenesis they express at least one angiogenetic protein or in the case of a desired inhibition of angiogenesis they express at least one anti-angiogenetic protein.
5. A method according to claim 4, wherein the cells obtained in step c) express an angiogenetic protein selected from PDGF-A (platelet derived growth factor A), PDGF-B (platelet derived growth factor B), VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), TGFbeta (tumour growth factor beta), angiopoetin 1 and angiopoetin.
6. A method according to claim 4, wherein the cells obtained in step c) express an anti-angiogenetic protein selected from VEGFR-1 (vascular endothelial growth factor receptor 1), angiostatin, endostatin and receptor blockers for VEGFR1 and VEGFR2.
7. The use of an agent according to any one of claims 1 to 3, or of an agent produced by

a method according to any one of claims 4 to 6, for inducing or inhibiting angiogenesis.

8. Use according to claim 7, in which an agent according to any one of claims 1 to 3 or an agent produced by a method according to any one of claims 4 to 6 is introduced into isogenic or autologous tissue of the body in which angiogenesis is to be induced or inhibited.